FibroGen, Inc (FGEN) Coverage Initiated by Analysts at Mizuho
Mizuho initiated coverage on shares of FibroGen, Inc (NASDAQ:FGEN) in a research report released on Wednesday, Marketbeat reports. The firm issued a neutral rating and a $61.00 price target on the biopharmaceutical company’s stock.
Other equities analysts have also recently issued reports about the company. Jefferies Group LLC assumed coverage on FibroGen in a report on Monday, July 10th. They set a buy rating and a $50.00 price target on the stock. Leerink Swann reaffirmed an outperform rating and set a $82.00 target price (up from $52.00) on shares of FibroGen in a research report on Tuesday, August 8th. William Blair reaffirmed an outperform rating on shares of FibroGen in a research report on Wednesday, August 9th. Citigroup Inc. upped their target price on FibroGen from $48.00 to $65.00 and gave the stock a top pick rating in a research report on Tuesday, August 8th. Finally, BidaskClub raised FibroGen from a buy rating to a strong-buy rating in a research report on Saturday, June 24th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $65.67.
FibroGen (NASDAQ:FGEN) traded down 2.65% during mid-day trading on Wednesday, hitting $55.20. 723,955 shares of the stock were exchanged. The company’s market capitalization is $3.93 billion. The stock has a 50 day moving average price of $49.78 and a 200 day moving average price of $35.13. FibroGen has a 1-year low of $15.60 and a 1-year high of $60.15.
FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). The business had revenue of $29.00 million for the quarter, compared to the consensus estimate of $34.80 million. FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. On average, equities analysts anticipate that FibroGen will post ($1.81) earnings per share for the current fiscal year.
In other news, VP Pat Cotroneo sold 95,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $50.61, for a total transaction of $4,807,950.00. Following the transaction, the vice president now directly owns 173,366 shares of the company’s stock, valued at $8,774,053.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider K Peony Yu sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, July 10th. The stock was sold at an average price of $32.98, for a total value of $164,900.00. Following the transaction, the insider now directly owns 216,507 shares in the company, valued at $7,140,400.86. The disclosure for this sale can be found here. Insiders have sold 557,828 shares of company stock worth $26,758,047 over the last ninety days. 14.90% of the stock is owned by insiders.
Several large investors have recently modified their holdings of FGEN. Ameritas Investment Partners Inc. purchased a new stake in FibroGen in the 1st quarter valued at $111,000. Quantbot Technologies LP purchased a new stake in FibroGen in the 2nd quarter valued at $128,000. SG Americas Securities LLC raised its position in FibroGen by 6.5% in the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 412 shares during the last quarter. Amalgamated Bank purchased a new stake in FibroGen in the 2nd quarter valued at $237,000. Finally, BNP Paribas Arbitrage SA raised its position in FibroGen by 589.1% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,401 shares of the biopharmaceutical company’s stock valued at $239,000 after buying an additional 6,327 shares during the last quarter. 47.49% of the stock is currently owned by institutional investors.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.